BRAF-mutant advanced encorafenib

Shares of Array Biopharma Inc (NASDAQ: ARRY) continue its bull run Tuesday, climbing more than 6 percent after surging 81 percent Monday on the heels of its positive late-stage skin cancer trial results. The study evaluating encorafenib and binimetinib in patients with "untreaded or 1L...